Advanced Filters
noise

Boston, Massachusetts Clinical Trials

A listing of Boston, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,871 clinical trials
G Glenn J Hanna, MD

PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), N-803 (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies involved in …

18 years of age All Phase 2
J Jennifer Y Wo, MD

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma. This study involves the following interventions: Atezolizumab Bevacizumab Stereotactic body radiation therapy (SBRT)

18 years of age All Phase 1
D Donna Wheatley

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

18 years of age All Phase 1
G Grace Bizup, BA

HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease

This research study is evaluating a program that entails a healthcare at home intervention for people with advanced liver disease.

18 years of age All Phase N/A
A Ashna Saini

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of …

18 years of age All Phase 2
G Glenn J Hanna, MD

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes …

18 years of age All Phase 2
J Jeffrey Meyerhardt, MD, MPH

The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial

The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection. The names of the groups in this research study are: Group A: Prehabilitation program Group B: Usual Care

18 years of age All Phase N/A
R Rosemary Smith, B.S.

PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product

This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.

21 years of age All Phase 2
Y Yousif Alsaadi, B.S

A Future Thinking Intervention for Comorbid Tobacco Use Disorder and Bipolar Disorder

Future Self-BD is a 6-session virtual intervention that encourages participants to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. Each session will be conducted on HIPAA-compliant Zoom and led by the PI (Dr. Gold).

18 years of age All Phase N/A
J Jin Hui Joo, MD MA

Developing a Peer Support Intervention for Depression in SCD

The purpose of this study is to assess the feasibility, acceptability, and fidelity of an 8-week intervention where peer coaches will deliver depression care to adults 60 years of age or older who have depression and subjective cognitive decline.

60 years of age All Phase N/A

Simplify language using AI